Literature DB >> 7689596

Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein. VI. Suppression of adoptively transferred disease and differential effects of oral vs. intravenous tolerization.

A Miller1, Z J Zhang, R A Sobel, A al-Sabbagh, H L Weiner.   

Abstract

Antigen-driven tolerance is an effective method of suppressing cell-mediated immune responses. We have previously shown that oral administration of myelin basic protein (MBP) suppresses experimental autoimmune encephalomyelitis (EAE) when it is actively induced by MBP emulsified in complete Freund's adjuvant. In order to further study antigen-driven tolerance in this model, we investigated the effect of oral tolerization on adoptively transferred EAE and compared oral tolerance to intravenously (i.v.) administered MBP in both actively induced EAE and adoptively transferred EAE. Although orally tolerized animals were not protected from adoptively transferred EAE, spleen cells from orally tolerized animals suppressed adoptively transferred EAE when co-transferred with encephalitogenic cells or when injected into recipient animals at a different site at the time encephalitogenic cells were transferred. This suppression was mediated by CD8+ T cells, correlated with suppression of DTH responses to MBP, and was associated with decreased inflammation in the spinal cord. Unlike oral tolerization, spleen cells from i.v. tolerized animals did not suppress adoptively transferred EAE when co-transferred with encephalitogenic cells although i.v. tolerized animals were protected from adoptively transferred EAE. MBP peptides were then utilized to further characterize differences between i.v. and oral tolerization in the actively induced disease model. Both orally and intravenously administered MBP suppressed actively induced EAE. However, EAE was only suppressed by prior i.v. tolerization with the encephalitogenic MBP peptide 71-90, but not with the non-encephalitogenic peptide 21-40, whereas prior tolerization with 21-40 did suppress actively induced EAE when administered orally. These results suggest a different mechanism of tolerance is initiated by oral vs. intravenous administered antigen. Specifically, oral tolerization suppresses primarily by the generation of active suppression whereas the dominant mechanism of suppression associated with i.v. tolerization appears most consistent with the elicitation of clonal anergy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7689596     DOI: 10.1016/0165-5728(93)90235-q

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  14 in total

1.  Disproportionate recruitment of CD8+ T cells into the central nervous system by professional antigen-presenting cells.

Authors:  M J Carson; C R Reilly; J G Sutcliffe; D Lo
Journal:  Am J Pathol       Date:  1999-02       Impact factor: 4.307

Review 2.  T-cell based immunotherapy in experimental autoimmune encephalomyelitis and multiple sclerosis.

Authors:  Kate O'Brien; Bruno Gran; Abdolmohamad Rostami
Journal:  Immunotherapy       Date:  2010-01       Impact factor: 4.196

3.  Oral administration of Alequel, a mixture of autologous colon-extracted proteins for the treatment of Crohn's disease.

Authors:  Eran Israeli; Yaron Ilan
Journal:  Therap Adv Gastroenterol       Date:  2010-01       Impact factor: 4.409

4.  Bystander suppression of the immune response to human serum albumin in rats fed ovalbumin.

Authors:  A Dahlman-Höglund; U Dahlgren; S Ahlstedt; L A Hanson; E Telemo
Journal:  Immunology       Date:  1995-09       Impact factor: 7.397

Review 5.  Biochemical features of anergic T cells.

Authors:  C C Maier; M I Greene
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

Review 6.  Oral tolerance.

Authors:  W Strober; B Kelsall; T Marth
Journal:  J Clin Immunol       Date:  1998-01       Impact factor: 8.317

7.  Effect of multiple antigenic exposures in the gut on oral tolerance and induction of antibacterial systemic immunity.

Authors:  S Garg; V Bal; S Rath; A George
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

8.  Treatments targeting the T cell receptor (TCR): effects of TCR peptide-specific T cells on activation, migration, and encephalitogenicity of myelin basic protein-specific T cells.

Authors:  H Offner; R Jacobs; B F Bebo; A A Vandenbark
Journal:  Springer Semin Immunopathol       Date:  1999

9.  Galectin-1 is essential for the induction of MOG35-55 -based intravenous tolerance in experimental autoimmune encephalomyelitis.

Authors:  Elisabeth R Mari; Javad Rasouli; Bogoljub Ciric; Jason N Moore; José R Conejo-Garcia; Naveen Rajasagi; Guang-Xian Zhang; Gabriel A Rabinovich; Abdolmohamad Rostami
Journal:  Eur J Immunol       Date:  2016-05-25       Impact factor: 5.532

10.  Differential effects of oral versus intrathymic administration of polymorphic major histocompatibility complex class II peptides on mononuclear and endothelial cell activation and cytokine expression during a delayed-type hypersensitivity response.

Authors:  W W Hancock; S J Khoury; C B Carpenter; M H Sayegh
Journal:  Am J Pathol       Date:  1994-06       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.